Agilis Biotherapeutics Completes $8 Million Financing to Develop DNA-based Therapeutics for Rare Diseases

01-01-2014 Business Wire HealthComments (0)

Agilis BiotherapeuticsBiotechnologyRare diseases

Agilis Biotherapeutics, LLC, a synthetic biology-based company focused on rare genetic diseases, announced today that the company has completed an $8 million dollar financing. Proceeds from the financing will be used for Agilis’ initial focus on developing a treatment for Friedreich’s ataxia (FRDA) in collaboration with Intrexon Corporation (NYSE: XON), a leader in the field of synthetic biology. Agilis and Intrexon recently executed an Exclusive Channel Collaboration

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top